Review of diabetes management and guidelines during Ramadan

Journal of the Royal Society of Medicine

Volumn 103, Issue 4, 2010, Pages 139-147

  Karamat, Muhammad Ali ^a   Syed, Ateeq ^b   Hanif, Wasim ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^c SELLY OAK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FATTY ACID; FRUCTOSAMINE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; KETONE; LIPID; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; PIOGLITAZONE; PLACEBO; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL; UNINDEXED DRUG; VILDAGLIPTIN;

AUTONOMIC NEUROPATHY; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL STUDY; CONSULTATION; DEHYDRATION; DIABETES MELLITUS; DIABETIC DIET; DIET RESTRICTION; FATTY ACID OXIDATION; FLUID INTAKE; FRUCTOSAMINE BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; HEALTH STATUS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; INFORMATION RETRIEVAL; INSULIN RELEASE; KETOACIDOSIS; KETOGENESIS; LIPID METABOLISM; MEDICAL CARE; MEDLINE; MONOTHERAPY; NUTRITION; PATHOPHYSIOLOGY; PATIENT COUNSELING; PHYSICAL ACTIVITY; PHYSIOLOGY; PRACTICE GUIDELINE; RELIGION; RETINA VEIN OCCLUSION; REVIEW; RISK MANAGEMENT; RISK REDUCTION;

EID: 77950674069     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.2010.090254     Document Type: Review

References (32)

1. See http://en.wikipedia.org/wiki/Muslim-population
2. Hanif MW, Valsamakis G, Dixon A, et al. Detection of impaired glucose tolerance and undiagnosed type 2 diabetes in UK South Asians: an effective screening strategy. Diabetes Obes Metab 2008;10:755-762
3. Holt T, Kumar S. ABC of Diabetes. London: BMJ Publishing; 2003
4. Fazel M. Medical implications of controlled fasting. J R Soc Med 1998;91:453
5. Al-Arouj M, Bouguerra R, Buse J, et al. Recommendations for management of diabetes during Ramadan. Diabetes Care 2005;28:2305-2311
6. Qureshi B. Diabetes in Ramadan. J R Soc Med 2002;95:489-490
7. Chowdhury TA, Lasker SS. Controlling the Asian diabetic. Care of the Elderly Fasting and Feasting, September 2006
8. Takruri HR. Effect of fasting in Ramadan on body weight. Saudi Med J 1989;10:491-494
9. Ziaee V, Razaei M, Ahmadinejad Z, et al. The changes of metabolic profile and weight during Ramadan fasting. Singapore Med J 2006;47:409-414
10. Dikensoy E, Balat O, Cebesoy B, Ozkur A, Cicek H, Can G. The effect of Ramadan fasting on maternal serum lipids, cortisol levels and fetal development. Arch Gynecol Obstet 2009;279:119-123
11. Mafauzy M, Mohammed WB, Anum MY, Zulkifli A, Ruhani AH. A study of the fasting diabetic patients during the month of Ramadan. Med J Malaysia 1990;45:14-17
12. Ibrahim Salti, Eric Bénard, Bruno Detournay, et al. EPIDIAR Study Group. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) Study. Diabetes Care 2004;27:2306-2311
13. Yarahmadi Sh, Larijani B, Bastanhagh MH, et al. Metabolic and clinical effects of Ramadan fasting in patients with type II diabetes. J Coll Physicians Surg Pak 2003;13:329-332 (Pubitemid 36889644)
14. Akanji AO, Mojiminiyi OA, Abdella N. Beneficial changes in serum apo A-1 and its ratio to apo B and HDL in stable hyperlipidaemic subjects after Ramadan fasting in Kuwait. Eur J Clin Nutr 2000;54:508-513 (Pubitemid 30345402)
15. Alghadyan AA. Retinal vein occlusion in Saudi Arabia: possible role of dehydration. Ann Ophthalmol 1993;25:394-398
16. International Consensus Meeting. Morocco; 1995
17. White M, Bush J, Kai J, Bhopal R, Rankin J. Quitting smoking and experience of smoking cessation interventions among UK Bangladeshi and Pakistani adults: the views of community members and health professionals. J Epidemiol Community Health 2006; 60:405-411
18. See http://www.communitiesinaction.org/Ramadan
19. Sarween N, Bilkhu H, Bain S. Diabetic control during Ramadan. Diabetic Medicine 2006;23 (Suppl. 2):P386
20. Greenstein A, Malik R. Why are South Asians at greater risk of developing diabetes? Care of the Elderly Fasting and Feasting, September 2006
21. Mucha GT, Merkel S, Thomas W, Bantle JP. Fasting and insulin glargine in individuals with type 1 diabetes. Diabetes Care 2004;27:1209-1210 (Pubitemid 38579794)
22. Kassem HS, Zantout MS, Azar ST. Insulin therapy during Ramadan fast for Type 1 diabetes patients. J Endocrinol Invest 2005;28:802-805 (Pubitemid 43162834)
23. Kadiri A, Al-Nakhi A, El-Ghazali S, et al. Treatment of type 1 diabetes with insulin lispro during Ramadan. Diabetes Metab 2001;27:482-486 (Pubitemid 32852457)
24. Sari R, Balci MK, Akbas SH, Avci B. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res 2004;30:169-177 (Pubitemid 39243119)
25. Belkhadir J, el Ghomari H, Klöcker N, et al. Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide. BMJ 1993;307:292-295
26. Glimepiride in Ramadan (GLIRA) Study Group.. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care 2005;28:421-422
27. Mafauzy M. Repaglinide versus glibenclamide treatment of type 2 patients during Ramadan fasting. Diabetes Res Clin Pract 2002;58:45-53 (Pubitemid 34823624)
28. Cesur M, Corapcioglu D, Gursoy A, et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract 2007;75:141-147 (Pubitemid 44894596)
29. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-166
30. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 2008;93:3703-3716
31. Bruttomesso D, Pianta A, Mari A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999;48:99-105 (Pubitemid 29019358)
32. Akram J, De Verga V. Insulin lispro (Lys(B28), Pro(B29) in the treatment of diabetes during the fasting month of Ramadan. Ramadan Study Group. Diabet Med 1999;16:861-866 (Pubitemid 29498226)